Related Experiment Video
Updated: Jul 18, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
New HIV-drug inhibits in vitro bladder cancer migration and invasion
1Biomolecular Sciences Program, Cardiovascular Research Institute, Department of Anatomy, UCSF, San Francisco, CA 94143-0452, USA.
Objective:
The CXCR4/CXCL12 axis appears crucial in the metastasis of bladder cancer. Our aim was to evaluate the potency of the CXCR4 antagonist, 4F-benzoyl-TE14011 (4F-bTE), as an anti-metastatic drug in this disease. In this study, we assessed the ability of 4F-bTE to inhibit tumor cell motility, invasion through extracellular matrix (ECM), matrix metalloproteinase (MMP) secretion and cytoskeletal responses to chemokine.
Methods:
To assess the degree to which cells could migrate and invade ECM under various conditions, we used TCCSUP bladder cancer cells in a Boyden chamber system. To monitor actin polymerization, we stained cells on chamber slides with AlexaFluor 594 phalloidin. To measure matrix-metalloproteinase-2 and -9 (MMP) activity, we used gelatin zymography. To assess the effects of the CXCR4 antagonist 4F-bTE on each of the above parameters, we exposed bladder cancer cells either to chemokine CXCL12, alone, or to both CXCL12 and 4F-bTE. We also monitored cells for apoptotic and necrotic changes during drug treatment.
Results:
The CXCR4 antagonist 4F-bTE markedly decreased CXCL12-induced bladder cancer cell migration and ECM invasion in Boyden chamber assays. The antagonist also blocked chemokine-induced actin polymerization as well as the induction of MMP-2 and MMP-9 in these cells.
Conclusion:
The CXCR4 antagonist 4F-bTE has the potential to inhibit expression of the metastatic phenotype and may provide therapeutic value to patients.
Insights
The CXCR4 antagonist 4F-benzoyl-TE14011 (4F-bTE) effectively inhibits bladder cancer cell migration and invasion. This drug shows potential for treating metastatic bladder cancer by targeting the CXCR4/CXCL12 pathway.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The CXCR4/CXCL12 signaling pathway plays a critical role in bladder cancer metastasis.
- Targeting this pathway presents a potential therapeutic strategy for managing bladder cancer progression.
Purpose of the Study:
- To evaluate the efficacy of the CXCR4 antagonist 4F-benzoyl-TE14011 (4F-bTE) in inhibiting bladder cancer metastasis.
- To assess the drug's impact on cancer cell motility, extracellular matrix (ECM) invasion, and associated molecular mechanisms.
Main Methods:
- Utilized TCCSUP bladder cancer cells in Boyden chamber assays to measure migration and ECM invasion.
- Assessed actin polymerization via phalloidin staining and matrix metalloproteinase (MMP) activity using gelatin zymography.
- Investigated the effects of 4F-bTE on CXCL12-stimulated cells, monitoring for apoptosis and necrosis.
Main Results:
- 4F-bTE significantly reduced CXCL12-induced migration and ECM invasion of bladder cancer cells.
- The antagonist effectively inhibited chemokine-induced actin polymerization and the expression of MMP-2 and MMP-9.
- No significant apoptotic or necrotic changes were observed during drug treatment.
Conclusions:
- The CXCR4 antagonist 4F-bTE demonstrates potent anti-metastatic properties in bladder cancer models.
- 4F-bTE holds promise as a therapeutic agent for patients with metastatic bladder cancer by targeting the CXCR4/CXCL12 axis.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
09:243-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
Published on: September 13, 2018
